The oz weight loss injection explained: what UK clinical evidence says

What the SURMOUNT and STEP trials established about weight loss injections

The evidence base for injectable weight management is unusually robust. The SURMOUNT-1 trial, published in the New England Journal of Medicine, randomised 2,539 adults with obesity (without type 2 diabetes) to tirzepatide or placebo for 72 weeks. At the 15mg dose, participants lost around 20–22% of body weight on average. That is a level of reduction previously associated only with bariatric surgery in routine data.

The STEP 1 trial did the same for semaglutide 2.4mg: 68 weeks, a similar population, average weight loss of roughly 15%, a meaningful result by any clinical standard, and the foundation for NICE's recommendation of Wegovy (TA875). Both medicines work by mimicking gut hormones that signal fullness and slow gastric emptying; appetite falls, energy intake falls, and weight follows. The difference is that tirzepatide targets two receptors (GIP and GLP-1) while semaglutide targets one, which the SURMOUNT-5 head-to-head trial (NEJM, 2025) suggests accounts for tirzepatide's larger average reduction. Which result matters for any individual, though, is a clinical question, not a marketing one.

If you want a broader overview of how these medicines compare and what makes each distinct, the weight loss injection overview covers that ground in full.

What 'oz weight loss injection' actually refers to in the UK, and why the name matters

The colloquial 'oz injection' tag has attached itself to several different products at different times: Ozempic first, then semaglutide more broadly, and lately tirzepatide. It is worth being precise. Ozempic is semaglutide licensed for type 2 diabetes, not weight management. Prescribing it off-label for weight loss is outside its UK marketing authorisation; the NHS and MHRA are clear on this point. The medicines licensed specifically for weight management are Mounjaro (tirzepatide) and Wegovy (semaglutide), different brand names, same underlying compound as Ozempic in Wegovy's case, but a separate licence and a separate clinical evidence review.

This distinction is not bureaucratic hair-splitting. The licensing process determines which populations were studied, at which doses, under what safety monitoring. A prescriber working within a licensed indication has a published evidence base to work from. That is why the route to these medicines in the UK is a prescription issued after clinical assessment, and why the range of licensed weight loss injections looks the way it does: two options, both prescription-only, both backed by large trial programmes.

For context on what the NHS pathway looks like versus the private route, the NHS access guide sets out current eligibility thresholds and waiting-list realities plainly.

Side effects, storage, and what the first few weeks look like

The side-effect profile is dominated by gastrointestinal symptoms: nausea is the most commonly reported, followed by loose stools, constipation, indigestion, and burping. Most people find these are sharpest in the first week or two after starting, or after a dose step, and then ease. Fatigue and headache are less common but reported. Injection-site reactions (mild redness or tenderness) occur in some people and generally resolve quickly.

The MHRA issued a Drug Safety Update in January 2026 specifically on GLP-1 medicines, flagging acute pancreatitis as a known but uncommon risk: severe stomach pain that reaches through to the back, with or without vomiting, warrants urgent medical attention. You can report any suspected side effects via the MHRA Yellow Card scheme, something our clinical team actively encourages. Your prescriber and the Patient Information Leaflet supplied with your medicine are the right sources for anything specific to your situation.

Storage is straightforward for most people: both Mounjaro and Wegovy pens need to be kept refrigerated between 2°C and 8°C, many people keep theirs in the fridge door alongside everyday items, which works well as a routine anchor. The exact window for room-temperature storage before use is set out in the leaflet; never go by memory or a third-party source for that detail.

For anything related to the practicalities of injecting (site rotation, needle changes) the Mounjaro injection guide and the broader how-to resource on weight loss injections are worth reading before you start.

Who these medicines are licensed for, and what clinical assessment covers

Both tirzepatide and semaglutide are licensed for adults with a BMI of 30 or above, or 27 and above alongside at least one weight-related condition such as high blood pressure, high cholesterol, obstructive sleep apnoea, or prediabetes. Lower BMI thresholds apply for some ethnic backgrounds under UK guidance. That is the licensed eligibility range; whether a specific individual is suitable involves more than a number on a calculator.

A prescriber assessing suitability will consider medical history, current medicines, and contraindications, a history of pancreatitis, for example, or certain thyroid conditions, require a careful conversation. These medicines are not recommended during pregnancy, while breastfeeding, or for anyone trying to conceive; they are not licensed for under-18s. Women taking oral contraceptives starting tirzepatide are advised to use an additional non-oral method for the first four weeks of treatment and for four weeks after each dose increase, because the pill's absorption may be reduced during that window.

Cost is a reasonable thing to factor in. If you want to understand how private pricing is structured and what an all-inclusive price actually covers, the cost context guide lays that out without sales pressure. And if you are still working out which option fits your situation, the treatment overview is a good place to start before a consultation.

When you're ready to find out whether you're eligible, check your eligibility with our prescribers, the consultation is free, and a real clinician reviews your answers the same day.